Trials / Recruiting
RecruitingNCT05789056
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Quoin Pharmaceuticals · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QRX003, 4% Lotion | QRX003Topical Lotion containing 4% active drug (serine protease inhibitor) |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2023-03-29
- Last updated
- 2025-04-02
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05789056. Inclusion in this directory is not an endorsement.